Breast 2021 Jul 6;59:165-175. Epub 2021 Jul 6.
Department of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, No.123 Huifu West, Yuexiu District, Guangzhou, 510080, Guangdong, China; Shantou University Medical College, Shantou, 515041, Guangdong, China. Electronic address:
Background: The benefit of adjuvant cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors with endocrine therapy (ET) in hormone receptor-positive, human epidermal growth factor 2 receptor-negative (HR+/HER2-) early breast cancer (EBC) is uncertain. Hence, we performed a meta-analysis to determine the efficacy and safety of adjuvant CDK4/6 inhibitors plus ET and to identify potential preferred subpopulations for this regimen.
Methods: A literature search was conducted in PubMed, Embase, Cochrane databases up to Jan 15, 2021. Read More